Webinars

  • The Impact of Rapid Flu Testing Reclassification

  • PSA Webcast Executive Summary

  • Vitamin D Testing

    Join Clinical Lab Products for this free webcast, which will provide an overview of the laboratory approaches used to measure vitamin D and discuss key topics

  • POC Webinar Executive Summary

    DIAGNOSTIC TESTING AT THE POINT-OF-CARE:

    WEBINAR BY JOHN L. BENDER, MD, MBA, FAAPP

    MIRAMONT FAMILY MEDIINE

  • POC Webinar Slides

    DIAGNOSTIC TESTING AT THE POINT-OF-CARE BY JOHN L. BENDER, MD, MBA, FAAPP

    Access the slide deck from the presentation

  • Colorectal Cancer: An Overview of Risk Factors and Screening Tools

    Population screening has been shown to reduce mortality from colorectal cancer, a major leading cause of cancer and cancer death among both men and women worldwide. This webcast will examine current understandings about who is at increased risk for developing colorectal cancer, as well as evolving guidelines for when screening should be undertaken

  • Influenza Testing Today

    Early detection of infection with the flu virus—preferably within the first 48 hours after the first symptoms appear—can enable a physician to initiate antiviral therapy to relieve a patient’s symptoms and shorten the course of the illness. But getting such early results within an actionable timeframe relies on the use of advanced diagnostics that are not only fast—often providing results within 30 minutes—but also highly sensitive and specific to strains of the flu prevalent in the population.

  • Bacterial Vaginosis: Complications and Diagnostic Options

    Bacterial vaginosis (BV) is the most common vaginal infection among women aged 15 to 44. Although more than 50% of women with BV have no symptoms, prevalence in the United States has been reported to be around 21 million. Education and diagnostic testing approaches have not been heavily stressed.Join Clinical Lab Products for this free webcast that will provide an overview of bacterial vaginosis

  • Trichomonas: The Forgotten STI

    More prevalent than either syphilis or gonorrhea, Trichomonas vaginalis is estimated to infect as many as 173 million people worldwide every year—8 million in the United States alone. Yet, in spite of US healthcare costs potentially totaling as much as $36 million annually, there is no US control program for trichomonas, which remains an under-studied and almost forgotten sexually transmitted infection.

    Join Clinical Lab Products for this free webcast that will provide an overview of current knowledge about Trichomonas vaginalis